TY - JOUR
T1 - Investigation of luteal HCG supplementation in GnRH-agonist-triggered fresh embryo transfer cycles
T2 - a randomized controlled trial
AU - Svenstrup, Louise
AU - Möller, Sören
AU - Fedder, Jens
AU - Pedersen, Dorrit Elschner
AU - Erb, Karin
AU - Andersen, Claus Yding
AU - Humaidan, Peter
N1 - Copyright © 2023. Published by Elsevier Ltd.
PY - 2024/5
Y1 - 2024/5
N2 - RESEARCH QUESTION: Does splitting the human chorionic gonadotrophin (HCG) support in IVF cycles triggered by a gonadotrophin-releasing hormone agonist result in a better progesterone profile?DESIGN: Randomized controlled three-arm study, performed at the Fertility Clinic, Odense University Hospital, Denmark. Patients with 12-25 follicles ≥12 mm were randomized into three groups: Group 1 - ovulation triggered with 6500 IU HCG; Group 2 - ovulation triggered with 0.5 mg GnRH agonist, followed by 1500 IU HCG on the day of oocyte retrieval (OCR); and Group 3 - ovulation triggered with 0.5 mg GnRH agonist, followed by 1000 IU HCG on the day of OCR and 500 IU HCG on OCR + 5. All groups received 180 mg vaginal progesterone. Progesterone concentrations were analysed in eight blood samples from each patient.RESULTS: Sixty-nine patients completed the study. Baseline and laboratory data were comparable. Progesterone concentration peaked on OCR + 4 in Groups 1 and 2, and peaked on OCR + 6 in Group 3. On OCR + 6, the progesterone concentration in Group 2 was significantly lower compared with Groups 1 and 3 (P = 0.003 and P < 0.001, respectively). On OCR + 8, the progesterone concentration in Group 3 was significantly higher compared with the other groups (both P<0.001). Progesterone concentrations were significantly higher in Group 3 from OCR + 6 until OCR + 14 compared with the other groups (all P ≤ 0.003). Four patients developed ovarian hyperstimulation syndrome in Group 3.CONCLUSION: Sequential HCG support after a GnRH agonist trigger provides a better progesterone concentration in the luteal phase.
AB - RESEARCH QUESTION: Does splitting the human chorionic gonadotrophin (HCG) support in IVF cycles triggered by a gonadotrophin-releasing hormone agonist result in a better progesterone profile?DESIGN: Randomized controlled three-arm study, performed at the Fertility Clinic, Odense University Hospital, Denmark. Patients with 12-25 follicles ≥12 mm were randomized into three groups: Group 1 - ovulation triggered with 6500 IU HCG; Group 2 - ovulation triggered with 0.5 mg GnRH agonist, followed by 1500 IU HCG on the day of oocyte retrieval (OCR); and Group 3 - ovulation triggered with 0.5 mg GnRH agonist, followed by 1000 IU HCG on the day of OCR and 500 IU HCG on OCR + 5. All groups received 180 mg vaginal progesterone. Progesterone concentrations were analysed in eight blood samples from each patient.RESULTS: Sixty-nine patients completed the study. Baseline and laboratory data were comparable. Progesterone concentration peaked on OCR + 4 in Groups 1 and 2, and peaked on OCR + 6 in Group 3. On OCR + 6, the progesterone concentration in Group 2 was significantly lower compared with Groups 1 and 3 (P = 0.003 and P < 0.001, respectively). On OCR + 8, the progesterone concentration in Group 3 was significantly higher compared with the other groups (both P<0.001). Progesterone concentrations were significantly higher in Group 3 from OCR + 6 until OCR + 14 compared with the other groups (all P ≤ 0.003). Four patients developed ovarian hyperstimulation syndrome in Group 3.CONCLUSION: Sequential HCG support after a GnRH agonist trigger provides a better progesterone concentration in the luteal phase.
KW - Humans
KW - Female
KW - Chorionic Gonadotropin/administration & dosage
KW - Gonadotropin-Releasing Hormone/agonists
KW - Adult
KW - Embryo Transfer/methods
KW - Progesterone/blood
KW - Pregnancy
KW - Ovulation Induction/methods
KW - Fertilization in Vitro/methods
KW - Pregnancy Rate
KW - Oocyte Retrieval
KW - Luteal Phase/drug effects
UR - http://www.scopus.com/inward/record.url?scp=85186980707&partnerID=8YFLogxK
U2 - 10.1016/j.rbmo.2023.103415
DO - 10.1016/j.rbmo.2023.103415
M3 - Journal article
C2 - 38452605
SN - 1472-6483
VL - 48
SP - 103415
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
IS - 5
M1 - 103415
ER -